FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286298974> ?p ?o ?g. }

• W4286298974 endingPage "1561" @default.
• W4286298974 startingPage "1561" @default.
• W4286298974 abstract "1561 Background: Hazard ratio (HR)-based analyses used in oncology trials rely on the assumption of proportional hazards, i.e. a HR that is constant over time. Proportional hazards violations (PHVs) may lead to misinterpretation of trial results. Restricted mean survival time (RMST) is valid with non-proportional hazards and has received recent attention specifically for immunotherapy (IO) trials but has not been routinely adopted in oncology trial design as a whole. We aimed to comprehensively characterize the incidence and factors associated with PHVs among phase 3 oncology trials and assess RMST as an alternate measure of treatment effect in survival analysis. Methods: We used Clinicaltrials.gov to identify all superiority-design, 2-arm phase 3 cancer trials with time-dependent endpoints with published results through February 2020. We manually reconstructed patient-level data from published Kaplan-Meier (KM) curves, assessed PHVs with the Schoenfeld residual test (p <.05) and analyzed the RMST. To assess reconstruction accuracy, reported and reconstructed HRs were compared. Univariable logistic regression was used to assess the likelihood of PHVs by trial characteristic, with statistically significant factors (p <.05) included in a multivariable analysis. Concordance of RMST-based and HR-based analysis was established when both tests agreed as to the statistical significance of the comparison. Results: Of 342 KM comparisons eligible for reconstruction, 318 comparisons across 315 trials, enrolling 347,538 patients from 1989-2017, were accurately reconstructed and analyzed. PHVs were identified in 76/318 (23.9%) trials. There was no difference in likelihood of PHVs among IO vs non-IO trials (LR 2.31, 95% CI 0.30 – 17.85, P =.37), nor by disease site, year of trial initiation, or sample size. Few trials with PHVs (16/76) pre-specified a plan to account for non-proportional hazards in statistical design. Trials with an overall survival (OS) primary endpoint (PEP) were less likely to have PHVs than trials with a non-OS PEP (LR: 0.50, 95% CI 0.28 - 0.90, P =.02). Trials whose PEP was non-significant were more likely to have PHVs (LR 1.73, 95% CI 1.01 - 2.97, P =.047). No factor remained significantly associated with PHV in multivariable analysis. Overall, 291/318 (91.5%) KM comparisons were concordant. Among trials with PHVs, 5/76 were significant by RMST but not HR, and 5/76 were significant by HR but not RMST. Of these, 1 led to FDA drug approval, and 2 others are cited in NCCN guidelines. Conclusions: PHVs are common across all phase 3 cancer clinical trials. Attempts to account for PHVs in trial design are lacking despite the potential for trial misinterpretation in the event of non-proportional hazards. RMST-based analysis is broadly concordant with HR-based analysis and may aid in interpretation of trials with PHVs. Hence, we recommend that prospective trials include a priori a statistical plan to account for PHVs." @default.
• W4286298974 created "2022-07-21" @default.
• W4286298974 creator A5013128365 @default.
• W4286298974 creator A5022274372 @default.
• W4286298974 creator A5022727379 @default.
• W4286298974 creator A5026186757 @default.
• W4286298974 creator A5027113415 @default.
• W4286298974 creator A5033010930 @default.
• W4286298974 creator A5036616928 @default.
• W4286298974 creator A5042435815 @default.
• W4286298974 creator A5062204572 @default.
• W4286298974 creator A5062569366 @default.
• W4286298974 creator A5064269897 @default.
• W4286298974 creator A5087620078 @default.
• W4286298974 creator A5091279526 @default.
• W4286298974 date "2022-06-01" @default.
• W4286298974 modified "2023-10-14" @default.
• W4286298974 title "Incidence and impact of proportional hazards violations in phase 3 cancer clinical trials." @default.
• W4286298974 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.1561" @default.
• W4286298974 hasPublicationYear "2022" @default.
• W4286298974 type Work @default.
• W4286298974 citedByCount "1" @default.
• W4286298974 countsByYear W42862989742023 @default.
• W4286298974 crossrefType "journal-article" @default.
• W4286298974 hasAuthorship W4286298974A5013128365 @default.
• W4286298974 hasAuthorship W4286298974A5022274372 @default.
• W4286298974 hasAuthorship W4286298974A5022727379 @default.
• W4286298974 hasAuthorship W4286298974A5026186757 @default.
• W4286298974 hasAuthorship W4286298974A5027113415 @default.
• W4286298974 hasAuthorship W4286298974A5033010930 @default.
• W4286298974 hasAuthorship W4286298974A5036616928 @default.
• W4286298974 hasAuthorship W4286298974A5042435815 @default.
• W4286298974 hasAuthorship W4286298974A5062204572 @default.
• W4286298974 hasAuthorship W4286298974A5062569366 @default.
• W4286298974 hasAuthorship W4286298974A5064269897 @default.
• W4286298974 hasAuthorship W4286298974A5087620078 @default.
• W4286298974 hasAuthorship W4286298974A5091279526 @default.
• W4286298974 hasConcept C10515644 @default.
• W4286298974 hasConcept C120665830 @default.
• W4286298974 hasConcept C121332964 @default.
• W4286298974 hasConcept C126322002 @default.
• W4286298974 hasConcept C143998085 @default.
• W4286298974 hasConcept C160798450 @default.
• W4286298974 hasConcept C207103383 @default.
• W4286298974 hasConcept C44249647 @default.
• W4286298974 hasConcept C50382708 @default.
• W4286298974 hasConcept C535046627 @default.
• W4286298974 hasConcept C61511704 @default.
• W4286298974 hasConcept C71924100 @default.
• W4286298974 hasConceptScore W4286298974C10515644 @default.
• W4286298974 hasConceptScore W4286298974C120665830 @default.
• W4286298974 hasConceptScore W4286298974C121332964 @default.
• W4286298974 hasConceptScore W4286298974C126322002 @default.
• W4286298974 hasConceptScore W4286298974C143998085 @default.
• W4286298974 hasConceptScore W4286298974C160798450 @default.
• W4286298974 hasConceptScore W4286298974C207103383 @default.
• W4286298974 hasConceptScore W4286298974C44249647 @default.
• W4286298974 hasConceptScore W4286298974C50382708 @default.
• W4286298974 hasConceptScore W4286298974C535046627 @default.
• W4286298974 hasConceptScore W4286298974C61511704 @default.
• W4286298974 hasConceptScore W4286298974C71924100 @default.
• W4286298974 hasFunder F4320317949 @default.
• W4286298974 hasIssue "16_suppl" @default.
• W4286298974 hasLocation W42862989741 @default.
• W4286298974 hasOpenAccess W4286298974 @default.
• W4286298974 hasPrimaryLocation W42862989741 @default.
• W4286298974 hasRelatedWork W2118215538 @default.
• W4286298974 hasRelatedWork W2120574916 @default.
• W4286298974 hasRelatedWork W2128245076 @default.
• W4286298974 hasRelatedWork W2558534037 @default.
• W4286298974 hasRelatedWork W2969537103 @default.
• W4286298974 hasRelatedWork W2994686985 @default.
• W4286298974 hasRelatedWork W3202449578 @default.
• W4286298974 hasRelatedWork W3204434365 @default.
• W4286298974 hasRelatedWork W4322099846 @default.
• W4286298974 hasRelatedWork W4366463952 @default.
• W4286298974 hasVolume "40" @default.
• W4286298974 isParatext "false" @default.
• W4286298974 isRetracted "false" @default.
• W4286298974 workType "article" @default.